Robert Andrade's most recent trade in Fennec Pharmaceuticals Inc was a trade of 2,431 Common shares done . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 2,431 | 163,382 (0%) | 0% | 0 | Common shares | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2025 | 2,431 | 160,951 (0%) | 0% | 0 | Common shares | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.10 per share. | 22 May 2025 | 8,220 | 158,520 (0%) | 0% | 5.1 | 41,922 | Common shares |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2025 | 8,220 | 850,751 | - | - | Stock Options | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 16,667 | 150,300 (0%) | 0% | 0 | Common shares | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 1,042 | 133,633 (0%) | 0% | 0 | Common shares | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 1,042 | 132,591 (0%) | 0% | 0 | Common shares | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2025 | 75,000 | 827,722 | - | - | Restricted Share Unit | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2025 | 50,000 | 877,722 | - | - | Stock Options | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 1,042 | 131,549 (0%) | 0% | 0 | Common shares | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 1,042 | 130,507 (0%) | 0% | 0 | Common shares | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 1,042 | 129,465 (0%) | 0% | 0 | Common shares | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2024 | 1,042 | 128,423 (0%) | 0% | 0 | Common shares | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 15,816 | 689,184 | - | - | Stock Options | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.45 per share. | 18 Nov 2024 | 15,816 | 127,381 (0%) | 0% | 2.4 | 38,749 | Common shares |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2024 | 1,042 | 111,565 (0%) | 0% | 0 | Common shares | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 1,042 | 110,523 (0%) | 0% | 0 | Common shares | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2024 | 1,042 | 109,481 (0%) | 0% | 0 | Common shares | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2024 | 1,042 | 108,439 (0%) | 0% | 0 | Common shares | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,042 | 107,397 (0%) | 0% | 0 | Common shares | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 1,042 | 106,355 (0%) | 0% | 0 | Common shares | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 100,000 | 728,958 | - | - | Stock Option (right to buy) | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 50,000 | 778,958 | - | - | Restricted Share Unit (right to receive value of a share) | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 1,042 | 105,313 (0%) | 0% | 0 | Common shares | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 01 Apr 2024 | 12,500 | 104,271 (0%) | 0% | 0 | Common shares | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 10.90 per share. | 26 Mar 2024 | 13,975 | 91,771 (0%) | 0% | 10.9 | 152,346 | Common shares |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 10.64 per share. | 04 Jan 2024 | 15,000 | 134,721 (0%) | 0% | 10.6 | 159,600 | Common shares |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 10.41 per share. | 04 Jan 2024 | 15,000 | 119,721 (0%) | 0% | 10.4 | 156,150 | Common shares |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2023 | 25,000 | 605,000 | - | - | Common Shares | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.45 per share. | 28 Jun 2023 | 25,000 | 149,721 (0%) | 0% | 2.5 | 61,250 | Common shares |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 8.99 per share. | 28 Jun 2023 | 10,000 | 139,721 (0%) | 0% | 9.0 | 89,900 | Common shares |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 8.82 per share. | 28 Jun 2023 | 7,500 | 124,721 (0%) | 0% | 8.8 | 66,150 | Common shares |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 8.97 per share. | 28 Jun 2023 | 7,500 | 132,221 (0%) | 0% | 9.0 | 67,275 | Common shares |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 75,000 | 630,000 | - | - | Stock Option (right to buy) | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 37,500 | 667,500 | - | - | Restricted Share Unit (right to receive value of a share) | |
| Fennec Pharmaceuticals Inc | Robert Andrade | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 11.00 per share. | 25 Mar 2023 | 13,975 | 105,746 (0%) | 0% | 11.0 | 153,690 | Common shares |